Litcius/Paper detail

A RAS(ON) Multi-Selective Inhibitor Combination Therapy Triggers Long-term Tumor Control through Senescence-Associated Tumor-Immune Equilibrium in Pancreatic Ductal Adenocarcinoma

Caroline Broderick, Riccardo Mezzadra, Exequiel M. Sisso, Felix Mbuga, Rashi Raghulan, Almudena Chaves Perez, Amanda Kulick, Lingyan Jiang, Jingjing Jiang, Yu-Jui Ho, Janelle Simon, Eric Rosiek, Eric Chan, Aveline Filliol, Ronan Chaligné, Elisa de Stanchina, Ximo Pechuan-Jorge, Andrea Schietinger, Mallika Singh, Scott W. Lowe

2025Cancer Discovery15 citationsDOIOpen Access PDF

Abstract

Pharmacological inhibition of oncogenic RAS represents an attractive strategy to target pancreatic ductal adenocarcinoma (PDAC), an almost ubiquitously RAS-driven disease. However, initial responses to targeted monotherapy inhibition of active RAS can be followed by relapses, potentially driven by the persistence of drug-tolerant tumor cells. To target these "persister" cells, we investigated strategies to increase their immune visibility in mouse models of PDAC. We show that combining a RAS(ON) multi-selective inhibitor with the CDK4/6 inhibitor palbociclib drives persister cells into a senescent-like state, which coincides with improved tumor control and substantial remodeling of the tumor microenvironment. Combining RAS(ON) and CDK4/6 inhibition with a CD40 agonist results in durable regressions and CD4 T cell-dependent tumor-immune equilibrium. Our studies reveal a combinatorial approach that circumvents resistance to RAS(ON) inhibitor monotherapy in preclinical models and demonstrates a mechanism by which therapy-induced senescence can be reinforced by the immune system, resulting in durable tumor control. SIGNIFICANCE: Our preclinical studies highlight an opportunity to exploit the senescence program and CD4 T cell-mediated mechanisms to achieve long-term tumor-immune equilibrium and control with RAS-targeted therapies. This work advances our understanding of therapy-induced senescence and suggests new avenues for combination therapies with the potential to benefit patients with PDAC. See related commentary by Lasse Opsahl and Pasca di Magliano, p. 1537.

Topics & Concepts

Immune systemCancer researchTumor microenvironmentSenescenceBiologyImmunologyCell biologyCancer Immunotherapy and BiomarkersAdvanced Breast Cancer TherapiesPhagocytosis and Immune Regulation
A RAS(ON) Multi-Selective Inhibitor Combination Therapy Triggers Long-term Tumor Control through Senescence-Associated Tumor-Immune Equilibrium in Pancreatic Ductal Adenocarcinoma | Litcius